Recent research have focused on the intersection of GLP|GIP|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GLP agonists are widely employed for managing type 2 T2DM, their unexpected effects on motivation circuits, specifically mediated by dopaminergic networks, are receiving substantial focus. This article details… Read More